Literature DB >> 7562993

Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993.

H Y Chen1, M Yuan, D M Livermore.   

Abstract

Antimicrobial resistance among 1991 Pseudomonas aeruginosa isolates collected at 24 UK hospitals during late 1993 was surveyed. Three-hundred and seventy-two of the isolates were resistant, or had reduced susceptibility, to some or all of azlocillin, carbenicillin, ceftazidime, imipenem and meropenem, and the mechanisms underlying their behaviour were examined. Only 13 isolates produced secondary beta-lactamases: six possessed PSE-1 or PSE-4 enzymes and seven had novel OXA enzyme types. Those with PSE types were highly resistant to azlocillin and carbenicillin whereas those with OXA enzymes were less resistant to these penicillins. Chromosomal beta-lactamase derepression was demonstrated in 54 isolates, most of which were resistant to ceftazidime and azlocillin although susceptible to carbenicillin and carbapenems. beta-Lactamase-independent "intrinsic" resistance occurred in 277 isolates and is believed to reflect some combination of impermeability and efflux. Two forms were seen: the classical type, present in 195 isolates, gave carbenicillin resistance (MIC > 128 mg/L) and reduced susceptibility to ciprofloxacin and to all beta-lactam agents except imipenem; a novel variant, seen in 82 isolates, affected only azlocillin, ceftazidime and, to a small extent, meropenem. Resistance to imipenem was largely dissociated from that to other beta-lactam agents, and probably reflected loss of D2 porin, whereas resistance to meropenem was mostly associated with intrinsic resistance to penicillins and cephalosporins. Comparison of the present results with those of a similar study in 1982 revealed significant increases in the proportions of isolates with intrinsic resistance or stable derepression (p < 0.01, chi 2 test).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562993     DOI: 10.1099/00222615-43-4-300

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  44 in total

1.  An SHV-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa.

Authors:  T Naas; L Philippon; L Poirel; E Ronco; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  OXA-17, a further extended-spectrum variant of OXA-10 beta-lactamase, isolated from Pseudomonas aeruginosa.

Authors:  F Danel; L M Hall; B Duke; D Gur; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

3.  Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa.

Authors:  D Aubert; L Poirel; J Chevalier; S Leotard; J M Pages; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Antibiotic susceptibility of microorganisms at a general hospital in Lagos, Nigeria.

Authors:  O O Odusanya
Journal:  J Natl Med Assoc       Date:  2002-11       Impact factor: 1.798

Review 5.  Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact.

Authors:  Gerhard F Weldhagen; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 6.  Pseudomonas aeruginosa AmpR: an acute-chronic switch regulator.

Authors:  Deepak Balasubramanian; Hansi Kumari; Kalai Mathee
Journal:  Pathog Dis       Date:  2015-02-26       Impact factor: 3.166

7.  Practical approach for detection and identification of OXA-10-derived ceftazidime-hydrolyzing extended-spectrum beta-lactamases.

Authors:  H Vahaboglu; R Ozturk; H Akbal; S Saribas; O Tansel; F Coşkunkan
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

8.  Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different beta-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region.

Authors:  J I Campbell; O Ciofu; N Høiby
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

9.  Functional and structural characterization of the genetic environment of an extended-spectrum beta-lactamase blaVEB gene from a Pseudomonas aeruginosa isolate obtained in India.

Authors:  Daniel Aubert; Delphine Girlich; Thierry Naas; Shanta Nagarajan; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 10.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.